‘Unprecedented’ 73% Response Rate With Combo in Untreated RCC

SAN FRANCISCO — The combination of an immunotherapy and a vascular endothelial growth factor (VEGF) inhibitor resulted in a groundbreaking response rate in metastatic renal cell carcinoma (RCC), according to results of an ongoing phase 1b study. In a cohort […]